News Center


BEI Event

Roundtable: Bioethics, Social Responsibility + Health Equity in Pharma

September 15, 2023 8am-3pm

This year’s roundtable (in its 14th year) will focus on metrics + strategies for advancing bioethics, patient-centricity + health equity across the bio-pharmaceutical sector and amplifying + connecting participants’ work in these areas. Discussions may inform agenda-setting + metrics development for the Good Pharma Scorecard. Sessions will begin w/ opening remarks + transition to open discussion.


Other Event

2023 Trialscope Disclose Conference

July 17, 2023

This year’s Trialscope event featured keynote speakers Jennifer Miller, PhD, founding president of Bioethics International and director of the Good Pharma Scorecard; and David Evans, president and CEO of the Clinical Data Interchange Standards Consortium (CDISC). Topics included DEI data sharing.

This was a gathering of industry leaders, regulatory experts, and technology enthusiasts focused on cutting-edge insights to shape the future of clinical trial disclosure.


Other Event

National Health Council, 2022 Science of Patient Engagement Symposium

October 19, 2022October 20, 2022

The National Health Council hosts its 2022 Science of Patient Engagement Symposium, From Research to Action: Health Equity for All. Over the past ears, the COVID-19 pandemic has upended the world and magnified health inequities among historically underrepresented racial/ethnic groups. The science of understanding the patient has never been more important. Health equity research, where diverse patients are at the core of scientific inquiry, is imperative to tackling inequities.  BEI’s Founder, Jennifer E. Miller, PHD, will Keynote on Trust in Medical Research.


All Events


New York Times interviews our founder, Jennifer Miller, on FDA's clinical trial transparency pilot

The New York Times interviewed our founder, Jennifer Miller, on FDA Commissioner Dr. Scott Gottlieb's clinical trial transparency initiatives. She discussed his new pilot, launched last month, which selects 9 recently-approved drugs, whose sponsors (generally pharmaceutical companies) volunteer to participate, to post portions of Clinical Study Reports (CSRs) from their pivotal trials on FDA's website…

February 12, 2018

Big Data Probably Knows More About You Than Your Friends Do

This week we focused on the ethics of Big Data, publishing an article titled, Big Data Probably Knows More About You Than Your Friends Do, in Leaps Mag. The article discusses the promises and perils of big data and concludes with a way to manage your data wealth.  To read the full article click here.

February 7, 2018

All Posts


Metrics, baseline scores, and a tool to improve sponsor performance on clinical trial diversity: retrospective cross sectional study, BMJ Medicine

Objective To develop a measure for fair inclusion in pivotal trials by assessing transparency and representation of enrolled women, older adults (aged 65 years and older), and racially and ethnically minoritized patients.

Design Retrospective cross sectional study of sponsors of novel oncology therapeutics approved by the FDA 2012-2017

Results Between 2012 and  2017, the FDA approved 59 novel cancer therapeutics, submitted by 25 sponsors (all industry companies) on the basis of 64 pivotal trials. All 25 sponsors (100%) reported participant sex, 10 (40%) reported age, and six (24%) reported race and ethnicity. Although 14 (56%) sponsors had adequate representation of women in trials, only six (24%) adequately represented older adults, and four (16%) adequately represented racially and ethnically minoritized patients (black, Asian, Hispanic or Latinx). On overall fair inclusion, one sponsor scored 100% and the median sponsor score was 81% (interquartile range 75-87%). More than half of sponsors (13 (56%) of 25) fairly included women, 20% (n=5) fairly included older adults, and 4% (n=1) fairly included racially and ethnically minoritized patients in trials. 80% of product had pivotal trials that fairly included women, 24% fairly included older adults, and 5% fairly included racially and ethnically minoritized patients.

Varma T, Mello M, Ross JS, Gross CP, Miller JE., Metrics, baseline scores, and a tool to improve sponsor performance on clinical trial diversity: retrospective cross sectional study, 

Evaluation of Drug Trials in High, Middle, and Low-Income Countries and Local Commercial Availability of Approved Drugs

Question  How commonly are drugs commercially available in the countries where they were tested?

Findings  This cross-sectional study found that 5 years after their approval in the US, 15% of novel drugs (5 of 34 drugs) were approved in all countries where they were tested; among 70 countries contributing research participants, 7% (5 countries) received market access to the drugs they helped test within 1 year of US approval and 31% (22 countries) did so within 5 years. Approvals were faster in high-income countries, and access was lowest in African countries.

Meaning  These findings suggest that substantial gaps exist between where drugs are tested and where they become available to patients, raising concerns about the equitable distribution of research benefits.

Published: May 5, 2021. Miller JE et al. JAMA Network Open 10.1001/jamanetworkopen.2021.7075  

All Publications

Press and Media Inquires

Press and media inquiries can be directed to:

Jennifer E. Miller, PhD